The application relates to 4-(substituted amino)phenyl carbamate derivatives, or pharmaceutically acceptable salts or solvates thereof, as KCNQ2/3 potassium channel modulators, and methods of their uses.

There is provided a compound of formula I, having the structure: wherein R.sup.1 to R.sup.5 have the meanings given in the description. ##STR00001##

There is provided a compound of formula I, having the structure: wherein R.sup.1 to R.sup.5 have the meanings given in the description. ##STR00001##

Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.

Disclosed are compounds of Formula I, including all stereoisomers and salts thereof, ##STR00001##
wherein Q.sup.1, Q.sup.2 and R are as defined in the disclosure. Also disclosed is a method for preparing a compound of Formula I, comprising contacting a compound of Formula II ##STR00002## with a compound of Formula III ##STR00003## optionally in the presence of a catalyst or a base to form a compound of Formula I. Further disclosed is a method for preparing a compound of Formula IV, ##STR00004##
comprising reductively cyclizing a compound of Formula I in the presence of a reducing agent.

Disclosed are compounds of Formula I, including all stereoisomers and salts thereof, ##STR00001##
wherein Q.sup.1, Q.sup.2 and R are as defined in the disclosure. Also disclosed is a method for preparing a compound of Formula I, comprising contacting a compound of Formula II ##STR00002## with a compound of Formula III ##STR00003## optionally in the presence of a catalyst or a base to form a compound of Formula I. Further disclosed is a method for preparing a compound of Formula IV, ##STR00004##
comprising reductively cyclizing a compound of Formula I in the presence of a reducing agent.

The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

The present invention provides compounds, compositions thereof, and methods of using the same.

The present invention provides compounds, compositions thereof, and methods of using the same.